In a filing, Kiniksa Pharmaceuticals International Plc revealed its Officer Tessari Eben acquired Company’s shares for reported $0.54 million on Jul 14 ’25. In the deal valued at $28.72 per share,18,900 shares were bought.
Then, Tessari Eben sold 17,300 shares, generating $489,244 in total proceeds. Upon selling the shares at $28.28, the CHIEF OPERATING OFFICER now owns 61,563 shares.
Before that, Tessari Eben bought 17,300 shares. Kiniksa Pharmaceuticals International Plc shares valued at $489,171 were divested by the Officer at a price of $28.28 per share.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -2.47% to $28.09. Over the last five days, the stock has gained 3.23%. Kiniksa Pharmaceuticals International Plc shares have risen nearly 30.05% since the year began. Nevertheless, the stocks have risen 42.01% over the past one year. While a 52-week high of $30.69 was reached on 06/11/25, a 52-week low of $17.82 was recorded on 01/13/25.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 27.73, which if violated will result in even more drops to 27.37. On the upside, there is a resistance level at 28.67. A further resistance level may holdings at 29.26.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-06-13, dropping by -0.95 million shares to a total of 2.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 3.31 million shares. There was a decline of -40.13%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
